Treatment effects were modelled using data from the Prostate Testing for Cancer and Treatment (ProtecT) trial.

Involved or close pathologic margins after breast conserving surgery are associated with an increased risk for distant recurrence and mortality in women with early-stage invasive breast cancer, indicates a meta-analysis.

KRAS G12C mutations were detected in 3.7% of patients, most commonly in those with nonsquamous non-small-cell lung cancer (NSCLC) and NSCLC not otherwise subtyped, at rates of 7.5% and 6.9%, respectively, followed by cancer of unknown primary, colorectal cancer, and squamous NSCLC, at 4.1%, 3.5%, and 2.0%.

Objective The aim of this study was to compare the efficacy and toxicity of checkpoint inhibitors between RCTs and RWE studies in patients with advanced non-small cell lung cancer (NSCLC) or melanoma.

Results of a large systematic review and meta-analysis show that people with cancer have a significantly greater risk for death from SARS-CoV-2 infection than their cancer-free peers, particularly if they have lung or hematologic cancer.

The results were most sensitive to the time horizon, and the initial treatments received by patients diagnosed with metastatic cancer.

Quitting smoking around the time of receiving a lung cancer diagnosis is associated with significantly improved overall survival than continuing smoking, shows a meta-analysis published in the Journal of Thoracic Oncology .

The addition of tucatinib to trastuzumab plus capecitabine continues to confer an overall survival benefit in advanced HER2-positive breast cancer over longer follow-up, show phase 2 data.

Aromatase inhibitors significantly reduce the risk for breast cancer recurrence relative to tamoxifen in premenopausal women treated with ovarian function suppression, suggests a patient-level meta-analysis.

Based on the available data on ovarian cancer during pregnancy, we performed a review and meta-analysis to evaluate the efficacy and safety of platinum-based chemotherapy against ovarian cancer during pregnancy.

Authors: Monia Sisi, Michele Fusaroli, Andrea De Giglio, Francesco Facchinetti, Andrea Ardizzoni, Emanuel Raschi & Francesco Gelsomino Abstract Background The development of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) has improved the survival outcomes of patients with advanced ALK-rearranged non-small-cell lung cancer (NSCLC).

Objective To analyze the onset of adverse drug reactions (ADRs) related to the use of HER2-positive breast cancer treatments through a spontaneous reporting system (SRS) database.

DOI [Teaser] Key Points for Decision Makers The dominant approaches to modeling the cost effectiveness of immuno-oncology (IO) therapies in advanced non-small cell lung cancer are Markov and partitioned survival models.

Individuals with obesity tend to have worse cancer survival outcomes than those without obesity, unless they have lung cancer, renal cell carcinoma, or melanoma, show findings of a systematic review and meta-analysis.

Matteo Lambertini outlines the key take-home messages of their meta-analysis evaluating the reproductive and disease-specific outcomes of pregnancy in breast cancer survivors.

Delaying cancer treatment by even 4 weeks is associated with an increased mortality risk, say researchers who investigated the impact of delays across surgical, systemic therapy, and radiotherapy indications for seven tumor types.

The risk for contracting COVID-19 appears to be higher among cancer patients and survivors than the general population, according to a pooled meta-analysis.

The addition of CDK4/6 inhibitors to endocrine therapy is associated with improved outcomes in patients with hormone receptor-positive, HER2-negative metastatic breast cancer, shows a meta-analysis.

Intensive care admission, ventilation, and mortality rates among people with cancer and SARS-CoV-2 infection do not significantly differ to those among infected people without cancer, US study findings indicate.

In patients with early-stage breast cancer, shorter durations of adjuvant trastuzumab therapy are noninferior to the standard 1-year schedule with regard to disease-free survival, suggests an individual patient data meta-analysis.